Raltegravir: In treatment-naive patients with hiv-1 infection

Drugs

Volumn 70, Issue 5, 2010, Pages 631-642

  Croxtall, Jamie D ^a   Scott, Lesley J ^a  

^a Adis A Wolters Kluwer Business   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; OMEPRAZOLE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; INSOMNIA; LIPID BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; NAUSEA; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TYPING;

ADMINISTRATION, ORAL; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77949919965     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204590-000000000-00000     Document Type: Review

References (42)

1. Joint United Nations Programme on HIV/AIDS. 2009 AIDS epidemic update [online]. Available from URL http://data. unaids.org/pub/Report/2009/2009- epidemic-update-en.pdf [Accessed 2009 Dec 21].
2. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008 [online]. Available from URL: http://www.who.int/hiv/pub/towards-universal-access-report- 2008.pdf [Accessed 2008 Nov 26]
3. WHO. Global HIV prevalence has levelled off: improvements in surveillance increase understanding of the epidemic, resulting in substantial revisions to estimates [online]. Available from URL http://www.who.int/mediacentre/news/ releases/2007/pr61/en/print.html [Accessed 2008 Nov 26]
4. Havlir DV. HIV integrase inhibitors: out of the pipeline and into the clinic. N Engl J Med 2008 Jul 24; 359 (4): 416-418
5. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002 May 17; 51 (RR-7): 1-55
6. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1. J Acquir Immune Defic Syndr 2006; 41 (4): 439-446
7. Richman D, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18 (10): 1393-1401
8. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009; 49: 377-394
9. DHSS Panel on Antiretroviral Guidelines for Adults and Adolescents: a working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf [Accessed 2010 Jan 20]
10. Hammer SM, Eron Jr JJ, Reiss P. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300 (5): 555-570
11. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9 (8): 563-608
12. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe [online]. Available from URL http://europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of- HIV-Infected-Adults.pdf [Accessed 2010 Jan 20]
13. Adberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49 (5): 651-681
14. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4 (3): 236-248
15. Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs 2008; 68 (1): 131-138
16. Croxtall JD, Keam SJ. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009; 69 (8): 1059-1075
17. Palmisano L. Role of integrase inhibitors in the treatment of HIV disease: expert review of anti-infective therapy. Expert Rev Anti Infect Ther 2007; 5 (1): 67-75
18. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008; 51 (18): 5843-5855
19. Charpentier C, Karmochkine M, Laureillard D, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008; 9 (9): 765-770
20. Sedaghat AR, Siliciano RF, Wilke CO. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 2009; 14 (2): 263-271
21. Canducci F, Sampaolo M, Marinozzi MC, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009 Feb 20; 23 (No.4): 455-460
22. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009 Apr 1; 63 (4): 795-804
23. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways. J Virol 2009; 83 (22): 11440-11446
24. Fransen S, Karmochkine M, Huang W, et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009 Oct; 53 (10): 4522-4524
25. Ferns RB, Kirk S, Bennett J, et al. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009; 23 (16): 2159-2164
26. Buzon MJ, Dalmau J, Puertas MC, et al. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 2009; 24 (1): 17-25
27. Sichtig N, Sierra S, Kaiser R, et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009 Jul; 64 (1): 25-32
28. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2007; 46 (2): 125-133
29. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009 Nov; 52 (3): 350-356
30. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009 Sep 5; 374 (9692): 796-806
31. Lennox J, De Jesus E, Lazzarin A, et al. Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a phase III study of raltegravir-based vs. efavirenz-based therapy in treatment-naive HIV+ patients [abstract no. H-924b]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12; San Francisco (CA)
32. Merck and Co. Inc. Isentress (raltegravir): US prescribing information. Whitehouse Station (NJ): Merck and Co. Inc., 2009
33. European Medicines Agency. Raltegravir: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/isentress/emea-combined-h860en.pdf [Accessed 2009 Dec 4]
34. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol 2008; 48 (6): 726-733
35. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab Dispos 2007; 35 (9): 1657-1663
36. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43 (5): 509-515
37. Yilmaz A, Gisslen M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4 (9): e6877
38. Nachman S, Samson P, Acosta E, et al. Pharmacokinetic (PK), safety, and efficacy data on cohort IIA; youth aged 6 to 11 years from IMPAACT P1066: a phase I/II study to evaluate raltegravir (RAL) in HIV-1 infected youth [abstract no. 873]. 17th Conference on Retro-viruses and opportunistic Infections; 2010 Feb 16-19; San Francisco (CA)
39. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther 2009 Jun; 85 (6): 623-627
40. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007 Nov 12; 21 (17): 2315-2321
41. Merck and Co. Inc. A study to evaluate the safety and efficacy of an investigational drug in HIV infected patients [ClinicalTrials.gov identifier NCT00100048]. US National Institutes of Health ClinicalTrials.gov [online]. Available from URL http://clinicaltrials.gov [Accessed 2010 Feb 3]
42. Cooper D, Steigbigel R, Lennox J, et al. Review of cancer incidence in raltegravir (RAL) clinical trials [abstract no. R-106]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal (QC)